Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

bowel cancer

  • Home
  •  
  • bowel cancer



  • Most Read
  • Latest Comments
  • After TGA and Chairman fiasco, Rhythm Biosciences concedes no commercial sales are possible for its bowel cancer kits
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • After TGA and Chairman fiasco, Rhythm Biosciences concedes no commercial sales are possible for its bowel cancer kits
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • After TGA and Chairman fiasco, Rhythm Biosciences concedes no commercial sales are possible for its bowel cancer kits
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • After TGA and Chairman fiasco, Rhythm Biosciences concedes no commercial sales are possible for its bowel cancer kits
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • After TGA and Chairman fiasco, Rhythm Biosciences concedes no commercial sales are possible for its bowel cancer kits
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Holista Colltech banks on new partners to turn fortunes as food sales struggle
    Holista Colltech banks on new partners to turn fortunes as food sales struggle
    • News

  • After TGA and Chairman fiasco, Rhythm Biosciences concedes no commercial sales are possible for its bowel cancer kits
    After TGA and Chairman fiasco, Rhythm Biosciences concedes no commercial sales are possible for its bowel cancer kits
    • News

  • The ASX listed biotech companies making their mark in oncology
    The ASX listed biotech companies making their mark in oncology
    • Opinion

  • Rhythm Biosciences nears commercialisation of revolutionary cancer test following filing of approval documents with the TGA
    Rhythm Biosciences nears commercialisation of revolutionary cancer test following filing of approval documents with the TGA
    • News

  • Rhythm Biosciences’ new clinical trial shows increases accuracy for their simple cancer blood test
    Rhythm Biosciences’ new clinical trial shows increases accuracy for their simple cancer blood test
    • News

  • After TGA and Chairman fiasco, Rhythm Biosciences concedes no commercial sales are possible for its bowel cancer kits
    • News

    After TGA and Chairman fiasco, Rhythm Biosciences concedes no commercial sales are possible for its bowel cancer kits

    Medical diagnostics company Rhythm Biosciences (ASX: RHY) has undertaken a comprehensive strategic review following major shareholder discontent and a subsequent S249D notice requesting a vote to remove the Chairman. In October, the Company faced regulatory scrutiny as its stock value plunged from 32¢ to 20¢, triggering an ASX “speeding ticket”. Later, the stock was trading

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.